<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03895411</url>
  </required_header>
  <id_info>
    <org_study_id>SJEX001</org_study_id>
    <nct_id>NCT03895411</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Sotalol in Children With Arrhythmia</brief_title>
  <official_title>Multicenter Clinical Study of Therapeutic Effect of Sotalol on Children With Arrhythmia (Paroxysmal Supraventricular Tachycardia, Paroxysmal Atrial Tachycardia, Ventricular Tachycardia, Idiopathic Ventricular Tachycardia, Premature Ventricular Contraction ) in Children Aged From 0d to 14 Yrs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shengjing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the efficacy and safety of oral sotalol alone or combination
      with other anti-arrhythmic medicines in the treatment of arrhythmias in children. The study
      will regularly monitor the Holter, electrocardiogram (ECG), Echocardiography (Echo), blood
      routine, urine routine, serum ion, liver and kidney function, troponin I, hypersensitive
      troponin T, N-terminal pro-brain natriuretic peptide (NT pro-BNP), etc, before and after
      receive sotalol therapy. Compare the degree of arrhythmia improvement in patients and the
      side effects after oral sotalol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Monitoring the Holter, ECG, Echocardiography , blood routine, urine routine, serum ion, liver
      and kidney function, troponin I, hypersensitive troponin T, NT pro-BNP beforehand. Eligible
      patients should stop all anti-arrhythmia drugs and digitalis, tricyclic antidepressants, beta
      blockers or calcium antagonists for at least 5 half-lives, and then do Holter. Randomly
      grouped. Judging the results according to the situation before and after oral sotalol.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QT interval of ECG</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>QT interval of ECG</measure>
    <time_frame>3 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>1 week, 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cell (RBC)</measure>
    <time_frame>1 week, 3 month</time_frame>
    <description>The indicator is obtained through blood routine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wed Blood Cell (WBC)</measure>
    <time_frame>1 week, 3 month</time_frame>
    <description>The indicator is obtained through blood routine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>1 week, 3 month</time_frame>
    <description>The indicator is obtained through blood routine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet</measure>
    <time_frame>1 week, 3 month</time_frame>
    <description>The indicator is obtained through blood routine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin</measure>
    <time_frame>1 week, 3 month</time_frame>
    <description>The indicator is obtained through liver function test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase (ALT)</measure>
    <time_frame>1 week, 3 month</time_frame>
    <description>The indicator is obtained through liver function test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspertate aminotransferase (AST)</measure>
    <time_frame>1 week, 3 month</time_frame>
    <description>The indicator is obtained through liver function test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>1 week, 3 month</time_frame>
    <description>The indicator is obtained through kidney function test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Arrhythmia</condition>
  <arm_group>
    <arm_group_label>Sotalol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral sotalol 2.5mg/kg/time, per 12h. Combination therapy: betaloc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propafenone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Propafenone 5mg/kg/time, pre 8h Combination therapy: betaloc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sotalol</intervention_name>
    <description>Oral sotalol 2.5mg/kg/time, per 12h</description>
    <arm_group_label>Sotalol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propafenone</intervention_name>
    <description>Oral Propafenone 5mg/kg/time, pre 8h</description>
    <arm_group_label>Propafenone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>betaloc</intervention_name>
    <description>Oral betaloc 0.5mg/kg/time ,pre 12h</description>
    <arm_group_label>Propafenone</arm_group_label>
    <arm_group_label>Sotalol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 0 day to 14 year-old

          2. Diagnosis of tachycardia (paroxysmal supraventricular tachycardia, paroxysmal atrial
             tachycardia, ventricular tachycardia, idiopathic ventricular tachycardia, premature
             ventricular contraction) and had an episode within 3 months; Premature Ventricular
             Contractions (PVC) (total 10000 times/d, or&gt;5000 times/d with multiple source PVC, or
             total &gt; 3000 times/d but with paired PVC+ multiple source PVC, or ventricular
             tachycardia);

          3. Although PVC≤ 10000 times/d, but there are obvious symptoms such as palpitation, chest
             tightness, fatigue, dizziness and other symptoms that need improvement.

          4. Signed informed consent before the trial

          5. Good compliance

        Exclusion Criteria:

          1. Heart failure that is ineffective in conventional treatment;

          2. Left ventricular ejection fraction (LVEF) ≤ 50%;

          3. Suffering from bronchial asthma;

          4. Resting sinus heart rate (HR) in newborns &lt;90 bpm; -8 yrs &lt;80 bpm; ≥ 8 yrs &lt;60 bpm;

          5. Corrected QT Interval (QTc) ≥ 450ms;

          6. II ° -III ° atrioventricular block (AVB);

          7. Severe liver, renal dysfunction, acute myocardial infarction, acute myocarditis,
             electrolyte imbalance have not been corrected;

          8. The child has undergone major surgery in the past 4 weeks;

          9. The child has participated in other clinical trials in the past 4 weeks;

         10. The child has digestive, nervous, circulatory, kidney or liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hong Wang, MD</last_name>
    <phone>86-18940251677</phone>
    <email>wanghong_64@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shenjing Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hong Wang, MD</last_name>
      <phone>86-18940251677</phone>
      <email>wanghong_64@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2019</study_first_posted>
  <last_update_submitted>March 27, 2019</last_update_submitted>
  <last_update_submitted_qc>March 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shengjing Hospital</investigator_affiliation>
    <investigator_full_name>Hong Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sotalol</mesh_term>
    <mesh_term>Propafenone</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Dear Sir/Madam Our study receives a grant from China Ministry of Science and Technology. We cannot decide whether the data could be shared. Hope you can understand.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

